Seikagaku Past Earnings Performance

Past criteria checks 3/6

Seikagaku's earnings have been declining at an average annual rate of -45.5%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 4% per year. Seikagaku's return on equity is 2%, and it has net margins of 4%.

Key information

-45.52%

Earnings growth rate

-44.79%

EPS growth rate

Pharmaceuticals Industry Growth	5.95%
Revenue growth rate	4.03%
Return on equity	1.96%
Net Margin	4.02%
Next Earnings Update	05 Aug 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Seikagaku makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:SKUN.F Revenue, expenses and earnings (JPY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 26	36,645	1,473	9,622	7,010
31 Dec 25	35,863	-755	9,911	7,125
30 Sep 25	37,074	-488	9,969	7,427
30 Jun 25	38,083	-887	10,077	7,777
31 Mar 25	39,374	1,214	10,176	7,643
31 Dec 24	39,274	2,573	9,746	7,573
30 Sep 24	38,362	2,015	9,602	7,317
30 Jun 24	36,574	2,200	9,280	7,303
31 Mar 24	36,213	2,186	8,960	7,484
31 Dec 23	34,678	1,309	8,789	7,694
30 Sep 23	34,259	1,197	8,445	7,954
30 Jun 23	34,810	2,630	8,235	8,002
31 Mar 23	33,456	2,236	7,959	7,951
31 Dec 22	32,868	1,997	7,818	8,505
30 Sep 22	31,579	1,855	7,509	8,610
30 Jun 22	31,374	1,574	7,214	8,756
31 Mar 22	34,851	3,733	7,028	9,005
31 Dec 21	34,994	7,747	7,085	7,684
30 Sep 21	34,659	8,305	6,982	7,476
30 Jun 21	32,474	7,385	6,929	7,530
31 Mar 21	27,662	4,262	6,809	7,209
31 Dec 20	26,215	821	6,617	7,800
30 Sep 20	26,620	903	6,834	7,405
30 Jun 20	27,965	-11,290	7,057	7,204
31 Mar 20	28,642	-10,839	7,292	6,877
31 Dec 19	30,038	-9,790	7,329	6,613
30 Sep 19	29,683	-10,434	7,274	6,868
30 Jun 19	28,807	2,020	7,138	6,873
31 Mar 19	28,384	2,244	7,144	7,148
31 Dec 18	28,360	1,825	7,252	8,250
30 Sep 18	28,936	2,284	7,270	8,490
30 Jun 18	29,893	4,203	7,390	8,413
31 Mar 18	30,175	3,922	7,337	8,408
31 Dec 17	30,862	4,656	7,212	7,218
30 Sep 17	29,999	4,324	7,157	6,930
30 Jun 17	28,822	2,423	7,104	7,100
31 Mar 17	29,589	1,787	7,225	7,834
31 Dec 16	29,653	1,042	7,246	8,781
30 Sep 16	30,093	1,650	7,310	9,009
30 Jun 16	31,475	1,833	7,372	9,163
31 Mar 16	30,962	2,578	7,297	8,649
31 Dec 15	30,884	3,625	7,212	8,082
30 Sep 15	31,229	3,904	7,071	8,498
30 Jun 15	29,707	3,431	6,900	8,309

Quality Earnings: SKUN.F has a large one-off gain of ¥1.1B impacting its last 12 months of financial results to 31st March, 2026.

Growing Profit Margin: SKUN.F's current net profit margins (4%) are higher than last year (3.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SKUN.F's earnings have declined by 45.5% per year over the past 5 years.

Accelerating Growth: SKUN.F's earnings growth over the past year (21.3%) exceeds its 5-year average (-45.5% per year).

Earnings vs Industry: SKUN.F earnings growth over the past year (21.3%) exceeded the Pharmaceuticals industry -4.8%.

Return on Equity

High ROE: SKUN.F's Return on Equity (2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/21 02:22
End of Day Share Price	2026/04/29 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seikagaku Corporation is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Akitada Iwasa	Daiwa Securities Co. Ltd.
Masao Yoshida	Ichiyoshi Research Institute Inc.
Ippei Koga	Marusan Securities Co. Ltd.